139 related articles for article (PubMed ID: 15811203)
1. CARDS on the table: should everybody with type 2 diabetes take a statin?
Lee JD; Morrissey JR; Mikhailidis DP; Patel V
Curr Med Res Opin; 2005 Mar; 21(3):357-62. PubMed ID: 15811203
[TBL] [Abstract][Full Text] [Related]
2. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
3. The collaborative atorvastatin diabetes study: preliminary results.
Owen OG
Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
[TBL] [Abstract][Full Text] [Related]
6. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
Betteridge J
Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
[TBL] [Abstract][Full Text] [Related]
7. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
8. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Hobbs FD
Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Tantikosoom W; Thinkhamrop B; Kiatchusakul S; Jarernsiripornkul N; Srinakarin J; Ojongpian S
J Med Assoc Thai; 2005 Mar; 88(3):399-406. PubMed ID: 15962651
[TBL] [Abstract][Full Text] [Related]
15. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
16. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
17. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
19. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
[TBL] [Abstract][Full Text] [Related]
20. Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?
Kwan BC; Beddhu S; Kronenberg F; Cheung AK
Nat Clin Pract Nephrol; 2006 Feb; 2(2):76-7. PubMed ID: 16932397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
